Answers are grounded in this paper and cite their sources.
Background Febrile infection-related epilepsy syndrome (FIRES) is a rare subtype of new-onset refractory status epilepticus, and dysregulated neuroinflammation, including interleukin-6 (IL-6) signaling, is thought to contribute to its pathogenesis. Tocilizumab is given to selected patients as cytokine-targeted immunotherapy, but whether its use is associated with long-term neurological recovery is unclear. Methods Following PRISMA guidance, we searched PubMed, Embase, Web of Science, WanFang, CNKI, and VIP from inception through September 22, 2026 (PROSPERO CRD420261362781). The primary outcome was favorable long-term neurological function, defined as modified Rankin Scale (mRS) <=3 at the last eligible follow-up at least 3 months after seizure onset. Outcome proportions were pooled separately for each exposure group with random-effects models. Between-group comparisons used study-clustered mixed-effects meta-regression, and studies with concurrent tocilizumab and control groups were also pooled directly. Results Twenty studies comprising 232 patients contributed to the primary analysis; 51 received acute-phase tocilizumab and 181 did not. The pooled favorable outcome proportion was 68.7% (95% CI 53.6%-80.6%) in the tocilizumab group and 46.8% (37.4%-56.4%) in the control group. Study-clustered meta-regression showed an arm-level association between tocilizumab exposure and favorable outcome (OR 2.81, 95% CI 1.34-5.90; P = 0.0062). In three studies with concurrent comparator groups, the direct pooled RR was 1.23 (95% CI 0.50-3.00; P = 0.6528). A sensitivity analysis excluding study arms containing outcomes that required narrative mRS reconstruction yielded a similar arm-level association (OR 2.91, 95% CI 1.32-6.41; P = 0.0079). In the primary clustered models, cognitive impairment was less frequent in tocilizumab arms, whereas epilepsy, movement disorder, ICU stay, and mechanical ventilation duration did not differ significantly. Conclusions Acute-phase tocilizumab exposure was associated with more favorable long-term neurological outcomes in pediatric FIRES, with similar findings after excluding study arms requiring narrative mRS reconstruction. However, direct comparative evidence remained limited; these findings should therefore be considered hypothesis-generating rather than evidence of treatment efficacy. Prospective multicenter studies are needed to clarify the role of IL-6-directed therapy in FIRES. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261362781 , identifier CRD420261362781.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: